Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

UroGen Pharma (URGN) Accumulated Depreciation & Amortization (2016 - 2025)

UroGen Pharma (URGN) has disclosed Accumulated Depreciation & Amortization for 10 consecutive years, with $4.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Depreciation & Amortization changed N/A year-over-year to $4.5 million, compared with a TTM value of $4.5 million through Sep 2025, changed N/A, and an annual FY2024 reading of $4.3 million, up 8.32% over the prior year.
  • Accumulated Depreciation & Amortization was $4.5 million for Q3 2025 at UroGen Pharma, up from $4.3 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $4.5 million in Q3 2025 and bottomed at $200000.0 in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $3.0 million, with a median of $3.5 million recorded in 2022.
  • The sharpest move saw Accumulated Depreciation & Amortization surged 1237.5% in 2022, then rose 8.32% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $2.2 million in 2021, then soared by 41.51% to $3.2 million in 2022, then grew by 25.46% to $4.0 million in 2023, then rose by 8.32% to $4.3 million in 2024, then rose by 5.42% to $4.5 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for URGN at $4.5 million in Q3 2025, $4.3 million in Q4 2024, and $4.1 million in Q2 2024.